Biovault Technical is proud to announce that it has been awarded a Wholesale Dealers Authorisation (WDA) license by the Medicines and Healthcare products Regulatory Agency (MHRA). This pivotal accreditation enables Biovault to distribute medicinal products, paving the way for innovative immune effector cell (IEC) therapies such as CAR-T treatments to be delivered across the South West Peninsula.
Expanding access to advanced therapies
The award of this license marks a significant step in advancing cancer treatment accessibility in the region. For the first time, patients in Devon and Cornwall will no longer need to travel to Bristol for life-changing CAR-T therapies. Instead, Derriford Hospital in Plymouth will now provide these cutting-edge treatments for blood cancers such as leukemia, transforming care for patients across an area of approximately 2,900 square miles.
what does this mean for car-t patients?
CAR-T therapy, a groundbreaking treatment that reprograms a patient’s immune cells to target and destroy cancer, has been a game-changer for patients with certain types of blood cancers. Biovault Technical's end-to-end logistics and storage capabilities ensure that:
Efficient Handling: Immune cells are collected from the patient, couriered to the relevant manufacturing site for transduction, cryopreserved, and securely returned to Biovault until the patient is ready for infusion.
Seamless Distribution: The company’s strategic agreements with hospital pharmacies streamline the delivery of treatments to hospitals.
Future Readiness: Biovault’s infrastructure supports the increasing adoption of CAR-T and other IEC therapies, providing storage and distribution solutions tailored to hospital and trust needs.
“This achievement highlights our commitment to innovation and patient care. We look forward to supporting healthcare providers in delivering these advanced therapies.”
a trusted partner for healthcare providers
Biovault is uniquely positioned to support the rollout of CAR-T therapies nationwide. With strong connections to manufacturers, ample storage capacity, and expertise in medicinal logistics, Biovault simplifies the process for healthcare providers, ensuring timely and reliable delivery of these life-saving treatments.
“We are excited to play a part in expanding access to CAR-T therapy in the South West,” said Biovault General Manager Ben Charles. “This achievement highlights our commitment to innovation and patient care, and we look forward to supporting healthcare providers in delivering these advanced therapies.”
transforming care in the south west
This new development underscores Biovault Technical's dedication to driving innovation in healthcare logistics. As CAR-T treatments become more widespread, Biovault is equipped to meet the demand, ensuring that these therapies are accessible to more patients while maintaining the highest standards of quality and care.